Pharming Group EBIT/Actif

Que fait Pharming Group ? Pharming Group N.V. generates revenue through the development and commercialization of protein replacement therapies and precision medicines for rare diseases. Its lead product, RUCONEST, is a recombinant C1 esterase inhibitor used to treat acute hereditary angioedema (HAE) attacks in adult and adolescent patients. The company also markets Joenja (leniolisib), an oral small molecule PI3K inhibitor for activated phosphoinositide 3-kinase delta syndrome. Pharming collaborates with Novartis under a development collaboration and license agreement, which likely contributes to its revenue streams. The company serves patients with rare diseases across the United States, Europe, and internationally through its therapeutic offerings. RUCONEST targets acute HAE attacks in adult and adolescent patients, while Joenja addresses activated phosphoinositide 3-kinase delta syndrome. Both products are commercialized by Pharming Group N.V. in the United States, Europe, and internationally. The development collaboration and license agreement with Novartis supports the company's product pipeline and revenue generation. Pharming focuses on rare disease treatments, leveraging its expertise in protein replacement therapies and precision medicines to address unmet medical needs. Pharming Group est l'une des entreprises les plus populaires sur Eulerpool.